Symphogen has received a $5 million milestone payment from Genentech, triggered by the initiation of a Phase 1b clinical trial evaluating DSTA4637S, an investigational medicine containing a Symphogen-generated antibody conjugated to an antibiotic agent for the potential treatment of Staphylococcus aureus infections.   The antibody was originally discovered by isolating antibodies from individuals exposed to S.aureus using Symphogen’s patented Symplex technology.   “Ge...